Portfolia’s Post

🚀 Portfolio Spotlight: Hera Biotech Endometriosis affects 1 in 10 women globally, yet diagnosis has remained invasive and imprecise—until now. Hera Biotech, one of our FemTech III Fund companies, is revolutionizing diagnostics with MetriDx™, the world's first non-surgical diagnostic for endometriosis. We’re proud to back companies creating solutions that improve lives and expand healthcare innovation. 💙 Want to join the movement of women transforming healthcare? Learn more here: https://lnkd.in/gb58SMYk #WomensHealth #Innovation #Portfolia #FemTech

  • No alternative text description for this image
Somer Baburek, MBA

CEO - Hera Biotech - Taking endo diagnosis from surgical to simple

1w

Thank you for the shout out!!

Dr. Hadas Ziso

Founder & CEO of EndoCure | FemTech | Here to make an impact on millions of lives

5d

Very happy for you, ‏Somer Baburek, MBA‏! Congrats, and keep up the important work!!

Betty Lou A.

CRO Business Development | Pharma | Biotech | Medical Devices | Relationship Builder | People connector| Women's Health expert & advocate | Regulatory | Reimbursement | Clinical Trials | Coach | Mentor | Scouter for life

5d

Keep shining---Your future is bright! Somer Baburek, MBA

Doron York

Chairman /CEO - City Side Ventures

6d

Congrats.

See more comments

To view or add a comment, sign in

Explore topics